Investigating the associations between uncarboxylated matrix gla protein as a proxy for vitamin K status and cardiovascular disease risk factors in a general adult population.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Steinkopff Country of Publication: Germany NLM ID: 100888704 Publication Model: Electronic Cited Medium: Internet ISSN: 1436-6215 (Electronic) Linking ISSN: 14366207 NLM ISO Abbreviation: Eur J Nutr Subsets: MEDLINE
    • Publication Information:
      Original Publication: Darmstadt, Germany : Steinkopff, 1999-
    • Subject Terms:
    • Abstract:
      Purpose: Vitamin K is an activator of vitamin K dependent proteins, one of which is the potent inhibitor of vascular calcification, matrix Gla protein (MGP). The purpose of this study is to investigate the association between an inverse proxy of functional vitamin K status, plasma dephospho-uncarboxylated MGP (dp-ucMGP), and cardiovascular disease risk factors (CVDRFs).
      Methods: In a cross-sectional population-based health examination study of 4,092 individuals aged 24-77 years, the vitamin K status was assessed using plasma dp-ucMGP. All participants were linked to Danish National Prescription Register to obtain information on the use of vitamin K antagonists. The associations between log2 transformed dp-ucMGP values and CVDRFs were determined using regression models adjusted for sex, age, lifestyle factors, kidney function and waist circumference.
      Results: Higher dp-ucMGP levels were associated with increased risk of central obesity (Odds Ratio (OR) 4.76, 95% Confidence Intervals (CI) 3.57-6.34), diabetes (OR 1.96, 95% CI 1.11-3.45), hyperlipidaemia (OR 1.43, 95% CI 1.01-2.03), and impaired kidney function (OR 9.83, 95% CI 5.49-17.59) per doubling in dp-ucMGP. Dp-ucMGP was not independently associated with hypertension or arterial stiffness.
      Conclusion: Higher dp-ucMGP levels were associated with central obesity, diabetes, hyperlipidaemia, and impaired kidney function. Prospective studies and intervention studies examining the effects of improving vitamin K status are needed to clarify the potential role of vitamin K in relation to these CVDRFs.
      Competing Interests: Declarations. Conflict of interest: A. Linneberg has received an unrestricted grant and investigational products from Kappa Bioscience A/S for an intervention trial (The InterVitaminK Trial; clinicatrials.gov identifier NCT05259046) using vitamin K supplements as the active intervention. The remaining other authors declare no personal or financial conflict of interest.
      (© 2024. The Author(s).)
    • References:
      Eur J Clin Nutr. 2018 Jan;72(1):136-141. (PMID: 28952607)
      Nutrients. 2018 Mar 27;10(4):. (PMID: 29584693)
      Clin J Am Soc Nephrol. 2010 Apr;5(4):590-7. (PMID: 20167683)
      BMC Med. 2022 Jan 26;20(1):22. (PMID: 35078484)
      J Nutr. 2010 May;140(5):1029-34. (PMID: 20237066)
      Diabetes Care. 1994 Nov;17(11):1252-6. (PMID: 7821163)
      Thromb Haemost. 2010 Oct;104(4):811-22. (PMID: 20694284)
      J Nutr. 2011 Aug;141(8):1529-34. (PMID: 21628633)
      Curr Res Food Sci. 2022 Jan 29;5:306-312. (PMID: 35198989)
      Thromb Haemost. 2015 May;113(5):1135-44. (PMID: 25694037)
      Br J Nutr. 2001 Feb;85(2):219-25. (PMID: 11242490)
      Clin Biochem. 2020 Sep;83:49-56. (PMID: 32422228)
      JRSM Cardiovasc Dis. 2017 Jan 01;6:2048004016687211. (PMID: 28286646)
      Atherosclerosis. 2012 Dec;225(2):397-402. (PMID: 23062766)
      Blood. 2010 Jun 17;115(24):5121-3. (PMID: 20354170)
      Nutrients. 2020 Sep 23;12(10):. (PMID: 32977548)
      J Nutr Health Aging. 2016 Mar;20(3):325-33. (PMID: 26892582)
      J Am Soc Nephrol. 2011 Feb;22(2):387-95. (PMID: 21289218)
      Nutrients. 2016 Jan 02;8(1):. (PMID: 26729160)
      Trends Mol Med. 2013 Apr;19(4):217-26. (PMID: 23375872)
      Int J Epidemiol. 2011 Oct;40(5):1382-400. (PMID: 22039197)
      Tzu Chi Med J. 2022 Jul 26;35(1):44-50. (PMID: 36866348)
      J Hum Hypertens. 2016 Jul;30(7):418-23. (PMID: 26016598)
      Food Nutr Res. 2023 Oct 23;67:. (PMID: 37920674)
      Food Funct. 2018 Jan 24;9(1):450-462. (PMID: 29227493)
      Clin Epidemiol. 2017 Feb 23;9:127-139. (PMID: 28275316)
      Scand J Public Health. 2011 Jul;39(7 Suppl):38-41. (PMID: 21775349)
      Curr Med Chem. 2023;30(32):3702-3724. (PMID: 36453499)
      Int J Mol Sci. 2019 Mar 29;20(7):. (PMID: 30934817)
      Stat Med. 2005 Oct 15;24(19):2911-35. (PMID: 16152135)
      Ann Intern Med. 2023 Apr;176(4):433-442. (PMID: 36972540)
      Ther Clin Risk Manag. 2007 Jun;3(3):499-504. (PMID: 18488070)
      Eur J Prev Cardiol. 2019 Mar;26(5):549-553. (PMID: 30348006)
      J Epidemiol Community Health. 2023 Feb;77(2):116-122. (PMID: 36446554)
      J Am Soc Nephrol. 2020 Jan;31(1):186-196. (PMID: 31704740)
    • Grant Information:
      F-12815-03-14-01 Danmarks Frie Forskningsfond; 7-11-0213 TrygFonden; 117548 TrygFonden; R155-2013-14070 Lundbeck Foundation; 22-B-0583 Helsefonden
    • Contributed Indexing:
      Keywords: Atherosclerosis; Cardiovascular disease risk factors; Epidemiology; Matrix Gla protein; Vitamin K
    • Accession Number:
      0 (Matrix Gla Protein)
      0 (Extracellular Matrix Proteins)
      0 (Calcium-Binding Proteins)
      12001-79-5 (Vitamin K)
      0 (Biomarkers)
    • Publication Date:
      Date Created: 20241120 Date Completed: 20241120 Latest Revision: 20241123
    • Publication Date:
      20241123
    • Accession Number:
      PMC11579057
    • Accession Number:
      10.1007/s00394-024-03532-6
    • Accession Number:
      39567396